Prognostic and predictive biomarkers in non-small cell lung carcinoma

Pathology, Journal Year: 2023, Volume and Issue: 56(2), P. 192 - 204

Published: Dec. 22, 2023

Language: Английский

---

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need

Published: May 3, 2023

The majority of EGFR mutations (85–90%) are exon 19 deletions and L858R point mutation 21, characterized by high sensitivity to EGFR-tyrosine kinase inhibitors (TKIs). Less is known about uncommon (10-15% mutations). Predominant types in this category include 18 mutations, 21 L861X, 20 insertions S768I. This group presents a heterogeneous prevalence, partly due the different testing methods presence compound mutation, which some cases leads shorter overall survival TKIs than simple mutations. EGFR-TKI may also vary depending on specific tertiary structure protein. best strategy remains uncertain data efficacy founded few prospective retrospective series. Newer investigational agents still under study there no other approved treatment targeting Defining option for patient population remain un unmet medical need. objective review evaluate existing outcomes, epidemiology clinical characteristics lung cancer patients with rare focus intracranial activity response immunotherapy.

Language: Английский

---

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations

Journal of Medicinal Chemistry, Journal Year: 2023, Volume and Issue: 66(17), P. 11656 - 11671

Published: Sept. 5, 2023

Epidermal growth factor receptor (EGFR) targeted therapy is one of the most important and effective strategies to combat EGFR mutant nonsmall-cell lung cancer (NSCLC). However, a substantial number patients bearing exon 20 insertion (Ex20ins) mutations respond poorly common therapies. This clinical need remained unmet until recently, when Ex20ins mutation inhibitor mobocertinib was approved by FDA. Despite this progress, structural mechanisms resistance characterization binding modes have not been systematically summarized. Herein, we analyze for ligand summarize recent developments reported inhibitors mutations. Furthermore, Perspective aims provide insights design next generation inhibitors.

Language: Английский

---

Thérapies moléculaires ciblées en cancérologie pulmonaire

Encyclopédie médico-chirurgicale. Pneumologie, Journal Year: 2025, Volume and Issue: 36(1), P. 1 - 9

Published: Jan. 1, 2025

---

Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting

Lung Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 108490 - 108490

Published: March 1, 2025

Language: Английский

---